Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy

Molecular BioSystems

Volumn 11, Issue 2, 2015, Pages 564-573

  Gehmlich, Katja ^a   Dodd, Michael S ^b   William Allwood, J ^c   Kelly, Matthew ^a   Bellahcene, Mohamed ^a   Lad, Heena V ^a   Stockenhuber, Alexander ^a   Hooper, Charlotte ^a   Ashrafian, Houman ^a   Redwood, Charles S ^a   Carrier, Lucie ^d,e   Dunn, Warwick B ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PERHEXILINE;

ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CARDIOMYOPATHY, HYPERTROPHIC; DISEASE MODEL; DRUG EFFECTS; ECHOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLISM; METABOLOME; METABOLOMICS; PATHOLOGY; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; MALE; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MICE, INBRED C57BL; MYOCARDIUM; PERHEXILINE; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS;

EID: 84921503968     PISSN: 1742206X     EISSN: 17422051     Source Type: Journal    
DOI: 10.1039/c4mb00594e     Document Type: Article

References (36)

1. B. J. Maron, Hypertrophic cardiomyopathy: a systematic review, JAMA, J. Am. Med. Assoc., 2002, 287(10), 1308-1320.
2. I. Ostman-Smith, J. W. Rossano and R. E. Shaddy, Hypertrophic cardiomyopathy: do sudden death prevention strategies in children differ between Europe and North America?, Curr. Opin. Cardiol., 2013, 28(2), 130-138.
3. H. Watkins, H. Ashrafian and C. Redwood, Inherited cardiomyopathies, N. Engl. J. Med., 2011, 364 (17), 1643-1656.
4. P. Richard, P. Charron, L. Carrier, C. Ledeuil, T. Cheav, C. Pichereau, A. Benaiche, R. Isnard, O. Dubourg, M. Burban, J. P. Gueffet, A. Millaire, M. Desnos, K. Schwartz, B. Hainque, M. Komajda and E. H. F. Project, Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy, Circulation, 2003, 107(17), 2227-2232.
5. B. J. Maron, Commentary and re-appraisal: surgical septal myectomy vs. alcohol ablation: after a decade of controversy and mismatch between clinical practice and guidelines, Prog. Cardiovasc. Dis., 2012, 54(6), 523-528.
6. B. J. Maron, Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy, Circulation, 2010, 74(11), 2271-2282.
7. P. Elliott and P. Spirito, Prevention of hypertrophic cardio-myopathy- related deaths: theory and practice, Heart, 2008, 94(10), 1269-1275.
8. C. Semsarian, Group, C. C. G. D. C. W., Guidelines for the diagnosis and management of hypertrophic cardiomyopathy, Heart, Lung Circ., 2011, 20(11), 688-690.
9. H. Ashrafian, C. Redwood, E. Blair and H. Watkins, Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion, Trends Genet., 2003, 19(5), 263-268.
10. J. G. Crilley, E. A. Boehm, E. Blair, B. Rajagopalan, A. M. Blamire, P. Styles, W. J. McKenna, I. Ostman-Smith, K. Clarke and H. Watkins, Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy, J. Am. Coll. Cardiol., 2003, 41(10), 1776-1782.
11. C. Ferrantini, A. Belus, N. Piroddi, B. Scellini, C. Tesi and C. Poggesi, Mechanical and energetic consequences of HCM-causing mutations, J. Cardiovasc. Transl. Res., 2009, 2(4), 441-451.
12. J. A. Kennedy, S. A. Unger and J. D. Horowitz, Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone, Biochem. Pharmacol., 1996, 52(2), 273-280.
13. F. M. Jeffrey, L. Alvarez, V. Diczku, A. D. Sherry and C. R. Malloy, Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate, J. Cardiovasc. Pharmacol., 1995, 25(3), 469-472.
14. H. Ashrafian, J. D. Horowitz and M. P. Frenneaux, Perhexiline, Cardiovasc. Drug Rev., 2007, 25(1), 76-97.
15. J. A. Kennedy, P. Mohan, M. A. Pelle, S. R. Wade and J. D. Horowitz, The effects of perhexiline on the rat coronary vasculature, Eur. J. Pharmacol., 1999, 370(3), 263-270.
16. J. D. Horowitz, I. K. Button and L. Wing, Is perhexiline essential for the optimal management of angina pectoris?, Aust. N. Z. J. Med., 1995, 25(2), 111-113.
17. K. Abozguia, P. Elliott, W. McKenna, T. T. Phan, G. Nallur-Shivu, I. Ahmed, A. R. Maher, K. Kaur, J. Taylor, A. Henning, H. Ashrafian, H. Watkins and M. Frenneaux, Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy, Circulation, 2010, 122(16), 1562-1569.
18. J. D. Horowitz and Y. Y. Chirkov, Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation, Circulation, 2010, 122(16), 1547-1549.
19. X. Yin, J. Dwyer, S. R. Langley, U. Mayr, Q. Xing, I. Drozdov, A. Nabeebaccus, A. M. Shah, B. Madhu, J. Griffiths, L. M. Edwards and M. Mayr, Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome, J. Mol. Cell. Cardiol., 2013, 55, 27-30.
20. N. Vignier, S. Schlossarek, B. Fraysse, G. Mearini, E. Kramer, H. Pointu, N. Mougenot, J. Guiard, R. Reimer, H. Hohenberg, K. Schwartz, M. Vernet, T. Eschenhagen and L. Carrier, Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiacmyosin-binding protein Cmutant levels in cardiomyopathic mice, Circ. Res., 2009, 105(3), 239-248.
21. B. Fraysse, F. Weinberger, S. C. Bardswell, F. Cuello, N. Vignier, B. Geertz, J. Starbatty, E. Kramer, C. Coirault, T. Eschenhagen, J. C. Kentish, M. Avkiran and L. Carrier, Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice, J. Mol. Cell. Cardiol., 2012, 52(6), 1299-1307.
22. C. Gedicke-Hornung, V. Behrens-Gawlik, S. Reischmann, B. Geertz, D. Stimpel, F. Weinberger, S. Schlossarek, G. Precigout, I. Braren, T. Eschenhagen, G. Mearini, S. Lorain, T. Voit, P. A. Dreyfus, L. Garcia and L. Carrier, Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice, EMBO Mol. Med., 2013, 5 (7), 1060-1077.
23. S. Schlossarek, D. R. Englmann, K. R. Sultan, M. Sauer, T. Eschenhagen and L. Carrier, Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy, Basic Res. Cardiol., 2012, 107(1), 235.
24. M. Ten Hove, S. Chan, C. Lygate, M. Monfared, E. Boehm, K. Hulbert, H. Watkins, K. Clarke and S. Neubauer, Mechanisms of creatine depletion in chronically failing rat heart, J. Mol. Cell. Cardiol., 2005, 38(2), 309-313.
25. W. B. Dunn, D. Broadhurst, P. Begley, E. Zelena, S. Francis-McIntyre, N. Anderson, M. Brown, J. D. Knowles, A. Halsall, J. N. Haselden, A. W. Nicholls, I. D. Wilson, D. B. Kell, R. Goodacre and C. Human Serum Metabolome, Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry, Nat. Protoc., 2011, 6 (7), 1060-1083.
26. W. B. Dunn, I. D. Wilson, A. W. Nicholls and D. Broadhurst, The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans, Bioanalysis, 2012, 4(18), 2249-2264.
27. M. Brown, D. C. Wedge, R. Goodacre, D. B. Kell, P. N. Baker, L. C. Kenny, M. A. Mamas, L. Neyses and W. B. Dunn, Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets, Bioinformatics, 2011, 27(8), 1108-1112.
28. L. W. Sumner, A. Amberg, D. Barrett, M. H. Beale, R. Beger, C. A. Daykin, T. W. Fan, O. Fiehn, R. Goodacre, J. L. Griffin, T. Hankemeier, N. Hardy, J. Harnly, R. Higashi, J. Kopka, A. N. Lane, J. C. Lindon, P. Marriott, A. W. Nicholls, M. D. Reily, J. J. Thaden and M. R. Viant, Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI), Metabolomics, 2007, 3(3), 211-221.
29. M. Brown, W. B. Dunn, P. Dobson, Y. Patel, C. L. Winder, S. Francis-McIntyre, P. Begley, K. Carroll, D. Broadhurst, A. Tseng, N. Swainston, I. Spasic, R. Goodacre and D. B. Kell, Mass spectrometry tools and metabolite-specific databases for molecular identification in metabolomics, Analyst, 2009, 134(7), 1322-1332.
30. J. D. Horowitz, S. T. Sia, P. S. Macdonald, A. J. Goble and W. J. Louis, Perhexiline maleate treatment for severe angina pectoris-correlations with pharmacokinetics, Int. J. Cardiol., 1986, 13(2), 219-229.
31. P. P. Dimitrow, A. Undas, P. Wolkow, W. Tracz and J. S. Dubiel, Enhanced oxidative stress in hypertrophic cardiomyopathy, Pharmacol. Rep., 2009, 61(3), 491-495.
32. K. Nakamura, K. F. Kusano, H. Matsubara, Y. Nakamura, A. Miura, N. Nishii, K. Banba, S. Nagase, K. Miyaji, H. Morita, H. Saito, T. Emori and T. Ohe, Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy, J. Card. Failure, 2005, 11(2), 117-123.
33. F. Côté, C. Fligny, Y. Fromes, J. Mallet and G. Vodjdani, Recent advances in understanding serotonin regulation of cardiovascular function, Trends Mol. Med., 2004, 10(5), 232-238.
34. C. Fligny, Y. Fromes, P. Bonnin, M. Darmon, E. Bayard, J. M. Launay, F. Cote, J. Mallet and G. Vodjdani, Maternal serotonin influences cardiac function in adult offspring, FASEB J., 2008, 22(7), 2340-2349.
35. J. V. Reid, Trial of tryptophan prophylaxis in patients liable to African cardiomyopathy, S. Afr. Med. J., 1970, 44(25), 732-735.
36. M. J. Sole, A. Shum and G. R. Van Loon, Serotonin metabolism in the normal and failing hamster heart, Circ. Res., 1979, 45(5), 629-634.